AU2015209481C1 - Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema - Google Patents

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema Download PDF

Info

Publication number
AU2015209481C1
AU2015209481C1 AU2015209481A AU2015209481A AU2015209481C1 AU 2015209481 C1 AU2015209481 C1 AU 2015209481C1 AU 2015209481 A AU2015209481 A AU 2015209481A AU 2015209481 A AU2015209481 A AU 2015209481A AU 2015209481 C1 AU2015209481 C1 AU 2015209481C1
Authority
AU
Australia
Prior art keywords
antibody
plasma kallikrein
binding
ser
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015209481A
Other languages
English (en)
Other versions
AU2015209481A1 (en
AU2015209481B2 (en
Inventor
Burt Adelman
Joseph BIEDENKAPP
Yung CHYUNG
Ryan Faucette
Ryan Iarrobino
Jon A. Kenniston
Daniel J. Sexton
Christopher Tenhoor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2015209481A1 publication Critical patent/AU2015209481A1/en
Publication of AU2015209481B2 publication Critical patent/AU2015209481B2/en
Priority to AU2020244370A priority Critical patent/AU2020244370B2/en
Application granted granted Critical
Publication of AU2015209481C1 publication Critical patent/AU2015209481C1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: DYAX CORP.
Priority to AU2024203436A priority patent/AU2024203436A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
    • C12Y207/03002—Creatine kinase (2.7.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2015209481A 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema Active AU2015209481C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020244370A AU2020244370B2 (en) 2014-01-21 2020-09-28 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
AU2024203436A AU2024203436A1 (en) 2014-01-21 2024-05-23 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461929716P 2014-01-21 2014-01-21
US61/929,716 2014-01-21
US201461944361P 2014-02-25 2014-02-25
US61/944,361 2014-02-25
US201462021397P 2014-07-07 2014-07-07
US62/021,397 2014-07-07
PCT/US2015/012212 WO2015112578A1 (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020244370A Division AU2020244370B2 (en) 2014-01-21 2020-09-28 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Publications (3)

Publication Number Publication Date
AU2015209481A1 AU2015209481A1 (en) 2016-08-25
AU2015209481B2 AU2015209481B2 (en) 2020-07-30
AU2015209481C1 true AU2015209481C1 (en) 2020-10-29

Family

ID=53681890

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015209481A Active AU2015209481C1 (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
AU2020244370A Active AU2020244370B2 (en) 2014-01-21 2020-09-28 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
AU2024203436A Pending AU2024203436A1 (en) 2014-01-21 2024-05-23 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020244370A Active AU2020244370B2 (en) 2014-01-21 2020-09-28 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
AU2024203436A Pending AU2024203436A1 (en) 2014-01-21 2024-05-23 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Country Status (18)

Country Link
US (2) US11084884B2 (cg-RX-API-DMAC7.html)
EP (2) EP3848057B1 (cg-RX-API-DMAC7.html)
JP (4) JP6845012B2 (cg-RX-API-DMAC7.html)
KR (3) KR20220107077A (cg-RX-API-DMAC7.html)
CN (2) CN106132442B (cg-RX-API-DMAC7.html)
AU (3) AU2015209481C1 (cg-RX-API-DMAC7.html)
BR (1) BR112016016916B1 (cg-RX-API-DMAC7.html)
CA (1) CA2937329C (cg-RX-API-DMAC7.html)
DK (1) DK3096798T3 (cg-RX-API-DMAC7.html)
EA (1) EA038532B1 (cg-RX-API-DMAC7.html)
ES (1) ES2856076T3 (cg-RX-API-DMAC7.html)
IL (3) IL246864B (cg-RX-API-DMAC7.html)
MX (2) MX387753B (cg-RX-API-DMAC7.html)
NZ (2) NZ723369A (cg-RX-API-DMAC7.html)
PL (1) PL3096798T3 (cg-RX-API-DMAC7.html)
PT (1) PT3096798T (cg-RX-API-DMAC7.html)
WO (1) WO2015112578A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201605342B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
JP2014506257A (ja) * 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
EP3456744B1 (en) 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
CN111704672B (zh) 2013-03-15 2024-06-04 武田药品工业株式会社 抗血浆激肽释放酶抗体
AU2014340450B2 (en) 2013-10-21 2020-05-21 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
US10101344B2 (en) 2013-10-21 2018-10-16 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EA038532B1 (ru) * 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
EP3286226A4 (en) * 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
PL3365685T3 (pl) * 2015-10-19 2021-08-02 Dyax Corp. Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu
US11286307B2 (en) * 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
IL265195B2 (en) * 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
IL315175A (en) 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co RNA biomarkers for hereditary angioedema
BR112020007405A2 (pt) * 2017-10-18 2020-12-08 Regenxbio Inc. Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
JP7365052B2 (ja) 2017-12-01 2023-10-19 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
US12083142B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
JP7727308B2 (ja) 2017-12-01 2025-08-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用
JP7273417B2 (ja) 2017-12-01 2023-05-15 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
US11414661B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
DK3732185T3 (da) 2017-12-29 2025-03-31 Suzhou Ribo Life Science Co Ltd Konjugater og fremstilling og anvendelse heraf
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
CN111655297A (zh) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
EP3903830A4 (en) 2018-12-28 2023-04-26 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
EP3938404A1 (en) * 2019-03-14 2022-01-19 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2020280438B2 (en) 2019-05-22 2025-03-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
JP7614650B2 (ja) * 2019-05-24 2025-01-16 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体並びに調製方法と使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120201756A1 (en) * 2011-01-06 2012-08-09 Dyax Corp. Plasma kallikrein binding proteins

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0296171A4 (en) 1986-03-03 1989-11-07 Brigham & Womens Hospital ASSESSMENT PROCEDURE FOR NEPHROTOXICITY.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ES2227545T3 (es) 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
CA2466034C (en) 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2005023870A1 (ja) 2003-09-04 2005-03-17 Riken ＴＧＦ－β活性化制御領域の切断面を認識する抗体
EP1713929A2 (en) 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
SI2374472T1 (sl) 2006-03-16 2018-11-30 Dyax Corp., Sestavki in postopki za zdravljenje oftalmoloških motenj
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
WO2009012571A1 (en) * 2007-07-20 2009-01-29 Genesys Venture Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
CA2695012A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
CN102264390A (zh) 2008-07-02 2011-11-30 新兴产品开发西雅图有限公司 Il6免疫治疗
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2012151247A2 (en) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
EP3456744B1 (en) 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
JP6656926B2 (ja) 2013-01-20 2020-03-04 ダイアックス コーポレーション ｐＫａｌ関連疾病の評価、アッセイおよび治療
CN111704672B (zh) 2013-03-15 2024-06-04 武田药品工业株式会社 抗血浆激肽释放酶抗体
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
AU2014340450B2 (en) 2013-10-21 2020-05-21 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
EP3286226A4 (en) 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112019005167A2 (pt) * 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
EP3678553B1 (en) 2017-09-05 2024-05-22 Sanolla Ltd Diagnosis of pathologies using infrasonic signatures
MX2021002349A (es) 2018-08-30 2021-05-31 Takeda Pharmaceuticals Co Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
EP3938404A1 (en) 2019-03-14 2022-01-19 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN115297927A (zh) 2020-01-13 2022-11-04 武田药品工业株式会社 血浆激肽释放酶抑制剂及其用于治疗儿科遗传性血管性水肿发作的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120201756A1 (en) * 2011-01-06 2012-08-09 Dyax Corp. Plasma kallikrein binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEXTON DANIEL ET AL, JOURNAL OF ALLERGY AND CLINICAL IMMUNO, ELSEVIER, AMSTERDAM, NL, (2013-02-26), vol. 131, no. 2, Suppl. S, doi:10.1016/J.JACI.2012.12.795, ISSN 0091-6749, page AB32 *
Ubc, "Dyax's DX-2930 granted Orphan Drug designation in hereditary angioedema", (2013-12-06), URL: http://www.ubc.com/dyaxs-dx-2930-granted-orphan-drug-designation-hereditary-angioedema, (2017-07-06) *

Also Published As

Publication number Publication date
ZA201605342B (en) 2020-11-25
NZ761006A (en) 2023-04-28
CA2937329A1 (en) 2015-07-30
KR20240049627A (ko) 2024-04-16
BR112016016916A2 (pt) 2018-01-23
KR20220107077A (ko) 2022-08-01
BR112016016916A8 (pt) 2018-05-02
AU2020244370B2 (en) 2024-03-07
PL3096798T3 (pl) 2021-07-26
AU2024203436A1 (en) 2024-06-13
AU2015209481A1 (en) 2016-08-25
CN106132442A (zh) 2016-11-16
JP7164502B2 (ja) 2022-11-01
KR102424183B1 (ko) 2022-07-26
JP2024170495A (ja) 2024-12-10
JP6845012B2 (ja) 2021-03-17
US20170002094A1 (en) 2017-01-05
EP3848057A1 (en) 2021-07-14
ES2856076T3 (es) 2021-09-27
CN106132442B (zh) 2023-07-14
KR20240033156A (ko) 2024-03-12
DK3096798T3 (da) 2021-03-01
CA2937329C (en) 2022-05-31
EP3096798A1 (en) 2016-11-30
IL263669A (en) 2019-01-31
US11084884B2 (en) 2021-08-10
IL278062B (en) 2022-06-01
JP2023015087A (ja) 2023-01-31
EA201691470A1 (ru) 2016-12-30
EP3096798B1 (en) 2020-11-25
EP3848057B1 (en) 2025-12-10
JP2017503820A (ja) 2017-02-02
PT3096798T (pt) 2021-02-25
WO2015112578A1 (en) 2015-07-30
AU2020244370A1 (en) 2020-10-29
EA038532B1 (ru) 2021-09-10
AU2015209481B2 (en) 2020-07-30
MX387753B (es) 2025-03-18
KR20160122169A (ko) 2016-10-21
US20210087293A1 (en) 2021-03-25
IL263669B (en) 2020-10-29
NZ723369A (en) 2022-12-23
US12384854B2 (en) 2025-08-12
MX2016009428A (es) 2017-04-13
ZA202004653B (en) 2022-01-26
IL246864B (en) 2018-12-31
JP2020002171A (ja) 2020-01-09
EP3096798A4 (en) 2017-08-23
MX2021013665A (es) 2021-12-10
BR112016016916B1 (pt) 2023-12-19
CN116585468A (zh) 2023-08-15
IL278062A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
AU2020244370B2 (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
AU2022203180A1 (en) Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
HK40057855A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
KR102903403B1 (ko) 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
HK40064044A (en) Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
EA046649B1 (ru) Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ CHYUNG, YUNG; SEXTON, DANIEL J.; TENHOOR, CHRISTOPHER; KENNISTON, JON A.; FAUCETTE, RYAN; IARROBINO, RYAN; BIEDENKAPP, JOSEPH AND ADELMAN, BURT

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 JUL 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ CHYUNG, YUNG; SEXTON, DANIEL J.; TENHOOR, CHRISTOPHER; KENNISTON, JON A.; FAUCETTE, RYAN; IARROBINO, RYAN; BIEDENKAPP, JOSEPH AND ADELMAN, BURT

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 23 JUL 2020

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): DYAX CORP.